glp-1 rheumatoid arthritis Medications and Arthritis: What the 2025 Research Actually Shows Glucagon-like peptide-1 receptor agonists in

Robert Kushner: I haven't seen that paper, but what I can say which I thought you were getting to is that when we look at the categorical weight loss in all these trials, so some people lose 5%, 10%, 20%, 25% over the course of the trial, if you then stop the medication, the individuals who lost the greatest amount of body weight actually are the ones that regain it the quickest

This is not a product endorsement

J Clin Invest 79, 616619 (1987)

The long-term data on GLP-1 medications is still developing, and for many people, the medication is not intended to be permanent

What are the risks of leaving obesity untreated

In 2025, Novo Nordisk was pushed to cut its sales forecasts for Wegovy, explicitly blaming the rise in compounded alternatives for lost revenue and a sharp decline in its share price